[go: up one dir, main page]

AR046929A1 - Piridopirimidinonas - Google Patents

Piridopirimidinonas

Info

Publication number
AR046929A1
AR046929A1 ARP040104173A ARP040104173A AR046929A1 AR 046929 A1 AR046929 A1 AR 046929A1 AR P040104173 A ARP040104173 A AR P040104173A AR P040104173 A ARP040104173 A AR P040104173A AR 046929 A1 AR046929 A1 AR 046929A1
Authority
AR
Argentina
Prior art keywords
hal
independently
atoms
cooa
het
Prior art date
Application number
ARP040104173A
Other languages
English (en)
Inventor
Helene Crassier
Karl-August Ackermann
Francesc Mitjans
Elisabet Rosell-Vives
Jaume Adan
Riera Marta Soler
Guenter Dr Hoelzemann
Alfred Dr Jonczyk
Wolfgang Dr Staehle
Wilfried Dr Rautenberg
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR046929A1 publication Critical patent/AR046929A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)

Abstract

Los compuestos de la formula (1) en donde R1, R2, R3, R4, R5 son cada uno, de modo independiente entre sí, H, A, OH, OA, alquenilo, alquinilo, NO2, NH2, NHA, NA2, Hal, CN, COOH, COOA, -OHet, -O-alquilen-Het, -O-alquilen-NR8R9, CONR8R9, CH(OH)-A o - C(=O)-A, dos radicales adyacentes seleccionados de R1, R2, R3, R4, R5 también son juntos -O-CH2-CH2-, -O-CH2-O-, -O-CH2-CH2-O-, -O-CA2-O- u -O-CF2-O-; R6, R7 son cada uno, de modo independiente entre sí, H, A, Hal, OH, OA o CN; R8, R9 son cada uno, de modo independiente entre sí, H o alquilo C1-6, en donde uno o dos grupos CH2 pueden estar reemplazados por átomos de O y/o N; Het es un heterociclo mono o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede estar insustituido o mono, di o trisustituido con Hal, A, OA, COOA, CN o el O del carbonilo (=O); A es alquilo C1-10, en donde también 1-7 átomos de H pueden estar reemplazados por F y/o Cl; X, X' son cada uno, de modo independiente entre sí, NH o están ausentes; Hal es F, Cl, Br o I; así como sus derivados, solvatos, sales tautomeros y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones, son inhibidores de las tirosina quinasas, en especial de la TIE-2, y de las Raf-quinasas, y pueden utilizarse para el tratamiento de tumores.
ARP040104173A 2003-11-13 2004-11-12 Piridopirimidinonas AR046929A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10352979A DE10352979A1 (de) 2003-11-13 2003-11-13 Pyridopyrimidinone

Publications (1)

Publication Number Publication Date
AR046929A1 true AR046929A1 (es) 2006-01-04

Family

ID=34559624

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104173A AR046929A1 (es) 2003-11-13 2004-11-12 Piridopirimidinonas

Country Status (10)

Country Link
US (1) US7547695B2 (es)
EP (1) EP1682548B1 (es)
JP (1) JP2007510679A (es)
AR (1) AR046929A1 (es)
AT (1) ATE443704T1 (es)
AU (1) AU2004288727A1 (es)
CA (1) CA2545558A1 (es)
DE (2) DE10352979A1 (es)
ES (1) ES2332319T3 (es)
WO (1) WO2005047283A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ES2288694T3 (es) 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas.
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
BRPI0508509A (pt) * 2004-03-08 2007-07-31 Merck Patent Gmbh métodos para alteração da secreção de insulina
JP2007529423A (ja) * 2004-03-11 2007-10-25 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 血清・グルココルチコイド誘導性キナーゼのモジュレータの使用を含む、神経精神疾患を治療するためのグルタミン酸受容体の調節方法
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004054215A1 (de) * 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
CA2614443C (en) * 2005-07-21 2011-03-22 F. Hoffmann-La Roche Ag Pyrido [2,3-d] pyrimidine-2,4-diamine compounds as ptp1b inhibitors
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
TW200800983A (en) * 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
CA2622725A1 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
CA2649000A1 (en) * 2006-04-12 2007-10-18 Merck Patent Gesellschaft Mit Beschraenkter Haftung N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CN113304154B (zh) * 2021-05-10 2024-06-21 澳门科技大学 嘧啶二酮类化合物作为微粒体前列腺素e2合酶抑制剂的应用
CN113930791B (zh) * 2021-10-15 2023-11-03 阜阳师范大学 一种吡啶并二嘧啶四酮类化合物的电合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679859B2 (en) * 1994-06-14 1997-07-10 Dainippon Sumitomo Pharma Co., Ltd. Novel compound, process for producing the same, and antitumor agent
JP2004517080A (ja) * 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
TW200800983A (en) * 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase

Also Published As

Publication number Publication date
US7547695B2 (en) 2009-06-16
WO2005047283A1 (de) 2005-05-26
AU2004288727A1 (en) 2005-05-26
US20070099910A1 (en) 2007-05-03
DE502004010131D1 (de) 2009-11-05
CA2545558A1 (en) 2005-05-26
JP2007510679A (ja) 2007-04-26
DE10352979A1 (de) 2005-06-09
ATE443704T1 (de) 2009-10-15
ES2332319T3 (es) 2010-02-02
EP1682548B1 (de) 2009-09-23
EP1682548A1 (de) 2006-07-26

Similar Documents

Publication Publication Date Title
AR046929A1 (es) Piridopirimidinonas
AR046748A1 (es) Derivados de amina que inhiben,regulan,y/o modulan tirosinaquinasas,composiciones farmaceuticas que los contienen,procedimientos de preparacion y compuestos intermediarios
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
AR039695A1 (es) Derivados de tiazol, uso de los mismos para preparar un medicamento y conjunto en envases (kit)
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR045462A1 (es) DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
AR075475A1 (es) Derivados heterociclicos de piperazina utiles como agentes herbicidas y proceso para combatir el crecimiento de plantas indeseadas.
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
AR045733A1 (es) Derivados de aminobencimidazol
AR059908A1 (es) Derivados de 4-(pirrolopiridinil)-pirimidinil-2-amina
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR066155A1 (es) Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
PE20170774A1 (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR096235A1 (es) Arilquinazolinas
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AR082722A1 (es) Derivados de pirimidina
AR046086A1 (es) Derivados de 1,3- benzoxazolilo como inhibidores de quinasa
AR081828A1 (es) Compuestos de biguanida y su uso para el tratamiento del cancer
AR089944A1 (es) Derivados de tetrahidro-quinazolinona
AR026352A1 (es) Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii.

Legal Events

Date Code Title Description
FB Suspension of granting procedure